Key result
Post-AMI discharge insulin linked to ~72% higher 5-year mortality in diabetes.
Why the study?
The merits of insulin use for diabetes treatment in patients with advanced atherosclerosis after acute myocardial infarction are debated.
Does insulin prescription at discharge increase all-cause mortality in diabetic patients after an acute myocardial infarction?
Observational (n=1,221)
Yes
Does insulin prescription at discharge increase all-cause mortality in diabetic patients after an acute myocardial infarction?
Hazard Ratio: 1.72 (95% CI 1.42–2.09)
p-value: p=<0.001
In diabetic patients surviving an acute myocardial infarction, insulin prescription at discharge is associated with a significantly increased risk of 5-year all-cause mortality, even after extensive adjustment and propensity matching.
Insulin at discharge associated with higher 5-year mortality in diabetic post-MI patients; leaves open causality versus confounding, requiring randomized trials before practice change.
BACKGROUND: Merits of insulin use for diabetes treatment in patients with advanced atherosclerosis are debated. This observational study conducted in diabetic patients after an acute myocardial infarction aimed to assess whether insulin prescription at discharge (IPD) was related to all-cause mortality during follow-up. METHODS: Subjects were diabetic patients admitted in intensive- or coronary-care units for acute myocardial infarction (consecutively recruited in 223 centres in France) and discharged alive from the hospital, with or without an IPD. Vital status after five years was obtained and the relationship between insulin prescription at discharge and survival was studied. RESULTS: Overall, 1221 diabetic patients were discharged alive and 38% had an IPD. Factors independently related to IPD were female gender, hospitalization in a public hospital, duration of diabetes, HbA1c level, smoking, peripheral artery disease, history of coronary heart disease and Killip class. After adjustment, IPD was independently related to all-cause mortality after five years of follow-up (adjusted hazard ratio = 1.72 (1.42-2.09), p<0.001). This increased mortality in subjects with IPD was also observed in propensity matched analyses, when subjects actually treated or actually not treated with insulin at discharge were compared in two groups matched on their computed probability of having had insulin prescribed. CONCLUSIONS: Insulin was preferably prescribed in seriously affected patients, regarding diabetes and cardiovascular risk. However, insulin prescription at discharge was associated with increased all-cause mortality after extensive adjustments for confounders. These results suggest possible intrinsic harmful effects of insulin in high-risk diabetic patients after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Bataille et al. (2017) conducted an observational in Acute myocardial infarction in diabetic patients (n=1,221). Insulin prescription at discharge vs. No insulin prescription at discharge was evaluated on All-cause mortality (HR 1.72, 95% CI 1.42-2.09, p=<0.001). Insulin prescription at discharge in diabetic patients after acute myocardial infarction was associated with increased 5-year all-cause mortality (adjusted HR 1.72; 95% CI 1.42-2.09; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: